凯信远达上涨7.69%，报1.583美元/股，总市值2452.49万美元

Core Viewpoint - CASI Pharmaceuticals (凯信远达) has shown significant revenue growth but continues to report a net loss, indicating potential challenges in profitability despite strong sales performance [1][2]. Financial Performance - As of March 31, 2025, CASI reported total revenue of $6.24 million, representing an 83.04% year-over-year increase [1]. - The company recorded a net loss attributable to shareholders of $10.75 million, which is a 12.83% decrease compared to the previous year [1]. Stock Performance - On August 8, CASI's stock price increased by 7.69%, reaching $1.583 per share, with a trading volume of $19,400 and a total market capitalization of $24.52 million [1]. Upcoming Events - CASI is scheduled to disclose its fiscal year 2025 mid-term report on August 15, with the actual date subject to company announcement [2]. Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in China [2]. - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [2]. - CASI's product and research pipeline addresses multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2].